IDEAYA Biosciences (IDYA) Common Equity (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Common Equity of $937.3 million for Q1 2026, down 8.37% sequentially from $1.0 billion in Q4 2025, and down 8.48% YoY from $1.0 billion in Q1 2025.
IDEAYA Biosciences (IDYA) Common Equity (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Common Equity for 9 years, with the latest figure at $937.3 million in Q1 2026.
- Quarterly Common Equity fell 8.48% year-over-year to $937.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $937.3 million (down 8.48% YoY) and the FY2025 annual result came in at $1.0 billion, down 3.42% from the prior year.
- Common Equity declined to $937.3 million in Q1 2026 per IDYA's latest filing, from $1.0 billion in the prior quarter.
- Over five years, Common Equity peaked at $1.2 billion in Q3 2024 and troughed at $269.3 million in Q2 2022.
- A 5-year average of $728.4 million and a median of $931.7 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2026: Common Equity jumped 180.19% in 2024, then retreated 8.48% in 2026.
- Over 5 years, Common Equity stood at $349.5 million in 2022, then jumped by 77.73% to $621.1 million in 2023, then jumped by 70.53% to $1.1 billion in 2024, then slipped by 3.42% to $1.0 billion in 2025, then decreased by 8.37% to $937.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $937.3 million, $1.0 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Bn |
| Mar 31, 2026 | 937.27 Mn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 1.09 Bn |
| Jun 30, 2025 | 959.65 Mn |
| Mar 31, 2025 | 1.02 Bn |
| Dec 31, 2024 | 1.06 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 931.66 Mn |
| Mar 31, 2024 | 935.31 Mn |
| Dec 31, 2023 | 621.09 Mn |
| Sep 30, 2023 | 508.05 Mn |
| Jun 30, 2023 | 501.61 Mn |
| Mar 31, 2023 | 333.81 Mn |
| Dec 31, 2022 | 349.46 Mn |
| Sep 30, 2022 | 368.77 Mn |
| Jun 30, 2022 | 269.32 Mn |
| Mar 31, 2022 | 288.67 Mn |
| Dec 31, 2021 | 301.51 Mn |
| Sep 30, 2021 | 317.63 Mn |